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Abstract
The most common class of drugs used to treat Attention Deficit-Hyperactivity Disorder (ADHD) are the central nervous 
stimulants. These drugs stimulate specific areas of the central nervous system and aim to reverse the symptoms of 
ADHD. Medication for ADHD can be divided into stimulants such as methylphenidate, dexamphetamine, and lisdex 
amphetaminedimesylate, and non-stimulants such as atomoxetine. This review evaluates and critically discusses the 
pharmacotherapeutics of and neuronal systems involved in two drugs - methylphenidate and atomoxetine - prescribed for 
the treatment of ADHD in a paediatric behaviour clinic where children are assessed and treated for ADHD and co-morbid 
conditions. The presentation and prevalence of ADHD in children is also discussed.
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Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is 
the most commonly diagnosed neuro behavioural disor-
der of childhood, affecting 5% of children worldwide [1]. 
ADHD is characterised by levels of impulsiveness, motor 
activity, distractibility, restlessness and inattention that 
are inconsistent with the child’s developmental level. 
Three subtypes have been recognised: inattentive, hy-
peractive/impulsive and combined (inattentive/hyperac-
tive/impulsive) [2]. While ADHD is widely recognised as 
a disorder of childhood in twenty to thirty percent of cas-
es it persists into adulthood and maybe accompanied by 
comorbid problems such as substance misuse and anxi-
ety [3]. ADHD often occurs alongside significant psychi-
atric conditions which include depression and anxiety. 
Learning difficulties, oppositional defiance and conduct 
disorders frequently co-exist with ADHD [4]. As many 
as one third of those diagnosed with autism display 
symptoms characteristic of ADHD. The two syndromes 
share many features, the most prevalent being attention 
deficit problems, impulsivity and hyperactivity. Individ-
uals diagnosed with autism, tend to display social and 
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communication difficulties and stereotyped or repetitive 
behaviours [5]. ADHD persists beyond childhood and 
into adulthood in about 40-65% of cases, affecting 4% 
of the adult population [6]. In adults ADHD is linked 
to a 25-fold increase in risk for institutionalization for 
delinquency, 10-fold increase of anti-social personality 
disorder, a 9-fold increased risk for imprisonment, and 
up to a 5-fold increase for drug abuse [7].
The Diagnostic Statistical Manual (DSM), published 
by The American Psychiatric Association sets out crite-
ria for the classification of mental disorders. The most 
recent edition (DSM-5) has changed how ADHD is diag-
nosed and there is now a shift in the way ADHD is clas-
sified. It will no longer be grouped with conduct disorder 
and oppositional disorder, but recognised as a neurode-
velopmental disorder. Emotional outbursts which previ-
ously came under the symptoms of ADHD now come 
under bipolar disorder [8]. There is no single, simple or 
definite test for ADHD. For a diagnosis to be made, a 
specialist assessment by a paediatrician or psychiatrist is 
required. The diagnosis is made by recognising patterns 
of behaviour, observations of the child ideally at home 
and in school. Some children may require specialised 
tests by a clinical or educational psychologist and occa-
sionally a computerised test may be carried out to aid di-
agnosis. Given the prevalence of ADHD, and the societal 
and personal impact of the condition from childhood to 
adulthood, effective treatment is crucial. The majority of 
children who receive specialist treatment tailored to their 
needs may benefit considerably.
Review
Pathobiology of ADHD
From the 1980s ADHD was thought to be due to 
small deficits in the frontal and basal ganglia regions of 
the brain [9]. This hypothesis was posed as a result of the 
effectiveness of psycho-stimulants, such as methylpheni-
date which had been shown to affect levels of frontal and 
striatal dopamine in animals. The theory was reinforced 
by the fact that frontal and striatal animal and human 
lesions cause ADHD-like symptoms. A greater under-
standing of ADHD, and the parts of the brain affected 
by it, has been made possible by modern neuroimag-
ing techniques such as Positron Emission Tomography 
(PET) and Magnetic Resonance Imaging (MRI). These 
studies not only showed earlier theories to be correct 
but also showed ADHD to be more than a problem of 
frontal and striatal deficits [10]. Neuroimaging studies 
have consistently demonstrated that relative to “normal” 
brains, children and adults with ADHD have abnormal-
ities in several late developing fronto-striatal, tempo-
ro-parietal and fronto-cerebellar neural networks known 
to mediate the self-monitoring, attention, inhibitory and 
timing functions that are compromised in ADHD. Ab-
normal brain structure has been observed in children 
and adults with ADHD - in total cerebral volumes, sev-
eral frontal brain regions, in the basal ganglia, the sple-
nium of the corpus callosum and the cerebellum [10,11]. 
Age was also associated with structural deficits, that is, 
the volume of basal ganglia in older patients was found 
to be within normal limits. This suggests that children 
may grow out of their striatal brain deficits. However 
in other brain regions, such as the frontal and tempo-
ro-parietal areas, adults with ADHD have been shown to 
suffer brain impairment similar to that of children with 
ADHD, suggesting that brain deficits in these regions 
persist into adulthood [12]. Longitudinal imaging stud-
ies discovered that compared with non-ADHD peers, 
the structural abnormalities observed in children with 
ADHD may be due to a delay in maturation [13]. This 
research confirms a long-held theory that ADHD results 
from a delay in brain maturation. Neuro-imaging has 
shown that ADHD patients not only display under-acti-
vation in the dorso-lateral and inferior frontal cortex and 
the basal ganglia, but also in other areas of the brain that 
are important in the regulation of inhibition, attention, 
motivation and affect [10,11].
Further studies have indicated that not only are iso-
lated areas of the brain affected in ADHD but commu-
nication between the different regions is also affected. 
Structural connectivity studies of ADHD patients have 
shown deficits in late developing white matter tracts 
connecting the front-striatal, fronto-parietal, fronto-cer-
ebellar and parieto-occipital regions [14]. Recent anal-
yses that investigated the extent to which brain regions 
work together have indicated that brain circuits are less 
interconnected in ADHD, both during rest and when 
performing cognitive tasks [14].
Nerve cells conduct electrical signals throughout the 
body and have particular intercellular connections with 
other cells and tissues [15]. Nerve cells comprise den-
drites whose function it is to receive information from 
other cells and pass the information to the cell body [16]. 
In the autonomic nervous system communication be-
tween nerve cells involves the connection of two neurons 
in tandem. As an action potential travels along the first 
nerve it encounters a structure at the end called a syn-
apse. The synapse is essentially a space called the synap-
tic cleft, which must be bridged for the impulse to reach 
the next nerve. The nerve carrying the original impulse is 
called the pre-synaptic neuron while the nerve receiving 
the impulse on the other side of the synaptic cleft is called 
the post-synaptic neuron. Chemicals known as neu-
rotransmitters are released into the synaptic cleft when 
an impulse reaches the end of the pre-synaptic neuron 
which causes the impulse to be generated [17]. The role 
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of the neurotransmitter substance is to transfer signals 
between the neurons across the synaptic cleft [18]. The 
main neurotransmitters in the brain are dopamine, nor-
epinephrine, 5-hydroxytryptamine (serotonin), Gluta-
mate, γ-Amino Butyric Acid (GABA) and acetylcholine. 
It is now believed that more than one neurotransmitter is 
released during this process and that there are two types 
of neurotransmitter: inhibitory and excitatory [18]. As 
the name suggests excitatory neurotransmitters stimu-
late brain activity whereas inhibitory neurotransmitters 
exert a calming effect on the brain. When excitatory neu-
rotransmitters are overactive, inhibitory neurotransmit-
ters are reduced. Having travelled across the synaptic 
cleft the neurotransmitters bind to receptor sites (similar 
to a key in a lock) and various physiological responses 
are initiated [15]. Studies using PET have shown that 
ADHD patients have deficits in underlying neurotrans-
mitter systems, most importantly the dopamine system 
[19].
Genetic studies have highlighted consistency in show-
ing certain genes influencing susceptibility to ADHD. 
Much of the data focuses on the dopamine D4 receptor 
gene which encodes a protein receptor that mediates the 
postsynaptic action of dopamine [20]. Dysfunction of 
catecholamine, and particularly dopamine neuronal sys-
tems, has been postulated to be involved in ADHD [21]. 
Dopamine has an important role in attentional, psycho-
motor, reinforcing and rewarding behaviours that are 
lacking in ADHD. Methylphenidate and amphetamine 
have been extensively used to treat ADHD to block do-
pamine and norepinephrine transporters thereby en-
hancing catecholamine neurotransmission [22].
Methylphenidate
Stimulant medication, in the form of the piperidine 
derivative methylphenidate, accounts for the majority of 
the prescribed medication for ADHD [23,24]. Methyl-
phenidate’s mode of action in ADHD is not fully under-
stood however it is believed that methylphenidate acti-
vates the cortex and brain stem arousal system. The mode 
of action is to increase the quantity of norepinephrine 
and dopamine at the synaptic cleft. Studies have shown 
that methylphenidate blocks the reuptake of dopamine 
and norepinephrine into the presynaptic neuron result-
ing in prolonged effects at the dopamine receptor [25].
In 2001 Jensen and colleagues published the results 
of one of the largest and longest multimodal treatment 
studies in ADHD. The study examined the efficacy of 
stimulant medication alone or in combination with be-
havioural therapy and involved 579 children over a 14 
month period. The dosing titration method and patient 
response to methylphenidate using the patient data was 
evaluated. The efficacy rate was found to be 77% with an 
the optimal dosage range of 10-50 milligrams per day 
[26].
Stimulants are administered orally, absorbed rapidly 
and completely from the gastrointestinal tract, and then 
cross the blood brain barrier into the central nervous 
system. Maximal clinical effect of stimulants is achieved 
approximately two hours post administration [27]. Ab-
sorption parallels with the acute release of neurotrans-
mitter at the synaptic clefts [28]. Methylphenidate is ex-
tensively metabolised by de-esterification to alpha-phe-
nyl-piperidine acetic acid which has no pharmacological 
activity [29]. Initially, timing the administration of stim-
ulant medication was reported as being one of the most 
challenging aspects of managing children with ADHD. 
Methylphenidate acts rapidly but is of short duration re-
quiring administration 2-3 times daily to maintain ade-
quate serum concentrations to permit school and home-
work to be completed. The effect should be allowed to 
diminish in time for a normal sleep pattern. There was 
concern and reluctance on the part of schools about 
administering medication throughout the school day 
which led to the development of the first extended re-
lease wax-matrix products in the mid-1980s. These drugs 
are effective for 6-8 hours which should cover the school 
day, however some children may require an additional 
dose at midday to provide adequate coverage in the late 
afternoon and early evening. The first of these modified 
release drugs to be developed was Concerta XL® (mod-
ified release methylphenidate hydrochloride). The BNF 
states that prescribers should specify the brand to be 
prescribed since different versions of modified-release 
preparations may not have the same clinical effect [30] 
therefore in this paper discussion of modified release 
methylphenidate hydrochloride refers only to Concerta 
XL®.
Concerta XL® is an extended-release tablet which 
uses osmotic pressure to distribute methylphenidate at 
a controlled rate [31]. The tablet contains an osmotical-
ly active tri-layer core surrounded by a semi-permeable 
membrane with an outer drug overcoat. The outer drug 
coat dissolves once it is in the relatively water-rich envi-
ronment of the gastrointestinal tract. This process hap-
pens within the first hour post-administration and pro-
vides an immediate effect.
Fluid then moves into the osmotic core which causes 
a polymer to expand and push the drug through a hole 
drilled into the drug layer of the tablet. The membrane 
is responsible for controlling the rate of water penetra-
tion and subsequent drug delivery in due course. It is 
designed so that 22% is released immediately and 78% 
is released over time [28]. Concerta XL® is taken once 
daily and provides effective serum methylphenidate con-
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been proven in clinical trials to offer 24 hour coverage 
of symptoms associated with ADHD in adults and chil-
dren. The most common side effects are gastrointestinal 
including nausea, vomiting, decreased appetite, weight 
loss, tiredness and fatigue [35]. Fortunately these symp-
toms are transient and treatment with atomoxetine is fa-
vourable to compared stimulants because of its relatively 
long duration of action with less exacerbation of tics in 
patients prone to developing this associated side effect 
[23]. Atomoxetine improves patient motivation, energy 
levels and self-perception; it also has a positive effect on 
social functioning, mood and attention [36].
Atomoxetine is administered orally and is rapidly and 
almost completely absorbed from the gastrointestinal 
tract. Absorption is minimally affected by food. At ther-
apeutic concentrations 98% of atomoxetine in plasma is 
bound to protein, primarily albumin [38]. Cytochrome 
P450 (CYP450) enzymes are essential for the metabolism 
of many medications. Although there are in excess of 50 
enzymes in the P450 class, 6 enzymes are responsible for 
metabolising 90% of drugs. The two most important en-
zymes are CYP3A4 and CYP2D6. Atomoxetine is me-
tabolised mostly in the liver by the cytochrome enzymes, 
primarily the CYP2D6 pathway to 4-hydroxyatomoxe-
tine [39]. Greater than 80% of the dose of atomoxetine 
is excreted in the urine as 4-hydroxyatomoxetine-O-glu-
curonide while approximately 13-22% is excreted in the 
faeces [39]. Atomoxetine can take 6-8 weeks to exert its 
pharmacological effects. Full benefits may not be ob-
served for 6 weeks and in some cases 10-12 weeks. Some 
children, however, respond quickly and may be sensitive 
to the medication with side effects such as abdominal 
complaints occurring in approximately 20% of children; 
liver complications have been reported but are extremely 
rare [40].
Conclusion
The pharmaceutical industry has invested in research 
and development for new preparations of stimulant 
medications for the treatment of ADHD. Treatment 
of ADHD has been vastly transformed by the develop-
ment of longer acting stimulant formulations which 
have significantly improved the management of adults, 
adolescents and children with ADHD. The development 
of longer acting stimulants has removed the burden of 
administrations of medication and hence improved the 
treatment of ADHD symptoms during school hours 
which previously had sometimes posed challenging. The 
new generation of stimulant and non-stimulant medica-
tions allows patients to take control of their symptoms. 
Many patients may tailor medication to suit their needs, 
for example students can increase medication if they 
require more concentration at certain times of the day 
when studying for exams. Children exhibiting mild to 
centrations over a 10-12 hour period, equivalent to im-
mediate release methylphenidate given three times daily 
[32]. As it is designed to release the drug at a controlled 
rate, the tablet must pass through the gastro-intestinal 
tract unchanged therefore patients must be able to swal-
low the tablet whole (membrane intact) with liquid; for 
this reason it may not be appropriate to prescribe for use 
in dysphagia or if gastro-intestinal lumen restricted [30]. 
The half-life of methylphenidate in adults following ad-
ministration of Concerta XL® is approximately 3.5 hours. 
According to Hill and Adrian [33], Concerta XL® is me-
tabolised in the tissues to ritalinic acid and then elimi-
nated from the body by urinary excretion with the drug 
is almost completely eliminated from the body within 24 
hours. When commencing Concerta XL®, careful titra-
tion of the dose is necessary so patients should be com-
menced on the lowest dose possible. An evaluation of the 
patient’s cardiovascular status, including blood pressure 
and heart rate, should be made and used as a baseline in 
addition to a comprehensive medical history.
Atomoxetine
Atomoxetine was the first non-stimulant drug ap-
proved for the treatment of ADHD. Atomoxetine is one 
of a number of drugs identified as a specific blocker of 
the presynaptic transporter. It is classified as a selective 
norepinephrine (noradrenaline) reuptake inhibitor, as it 
inhibits the reuptake of presynaptic norepinephrine by 
capturing norepinephrine present in the synaptic cleft 
and transporting the norepinephrine back into the pre-
synaptic nerve terminal. It has been shown to increase 
the release of norepinephrine and dopamine 3-fold in the 
prefrontal cortex without changing dopamine amounts 
in other parts of the brain unlike stimulants [34]. Ato-
moxetine is approved for use in children, adolescents 
and adults although its efficacy has not been studied in 
children under 6 years. The recommended doses range 
as follows: children aged 6-17 years (weighing up to 70 
kg) 500 micrograms/kg daily for first 7 days with dose 
increased according to response, maintenance dose 1.2 
mg/kg daily; children aged 6-17 years (weighing 70 kg 
and over) 40 mg daily for first 7 days with dose increased 
according to response, maintenance dose 80 mg daily; 
adult (weighing up to 70 kg) 500 micrograms/kg daily for 
first 7 days with dose increased according to response, 
maintenance dose 1.2 mg/kg daily; adult (weighing 70 kg 
and over) 40 mg daily for first 7 days with dose increased 
according to response, maintenance dose 80-100 mg dai-
ly; for all patients, the total daily maintenance dose may 
be given either as a single dose in the morning or two di-
vided doses with the last dose no later than early evening 
[30]. It has an advantage over stimulant treatments for 
ADHD as it is less likely to be abused. It is not scheduled 
as a controlled substance like methylphenidate and has 
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moderate symptoms, which may only cause difficulties 
in school, benefit from stimulant formulations with 6-8 
hours duration of action. For children with more severe 
or prolonged ADHD symptoms, use of a longer acting 
preparation may be necessary. Atomoxetine may be a 
good alternative for patients who are unable to tolerate 
stimulant medication because of side effects such as tics 
or anxiety. Atomoxetine is indicated for the long-term 
treatment of ADHD in children, adolescents and adults 
and has been proved effective for controlling symptoms 
that last throughout the day and into the evening with 
a decreased risk of user rebound. An added benefit of 
atomoxetine is its non-controlled status, which makes it 
easier for patients requiring more than one month sup-
ply and making it less likely to be abused. The pharma-
ceutical properties of medication for ADHD highlight 
the specialist knowledge required to make prescribing 
decisions and also the need to make careful health as-
sessments and monitor health while the patient remains 
on medication.
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